The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice.
BACKGROUND
Despite in vivo use now over several years, in particular for nuclear medicine imaging, the influences on pharmacokinetics of chain length and base sequence of radiolabeled oligomers has not been investigated.


METHODS
As test oligomer, morpholinos (MORFs), a DNA analogue, were radiolabeled with 99mTc via MAG3 and the pharmacokinetics in normal mice determined for 3 chain lengths (15, 18 and 25 mer) and 2 base sequences (MORF and its complement cMORF). In addition, LS174T-tumor bearing nude mice received the anti-CEA antibody MN14 (Immunomedics) conjugated either with MORF15 or MORF18 and subsequently received 99mTc-labeled cMORF15 or cMORF18 respectively in a pretargeting strategy.


RESULTS
In normal mice, after 1 hr, regardless of chain length or sequence, all labeled MORFs and cMORFs accumulated only slightly in all tissues (e.g. at 3 hr <0.15 ID%/g) except in kidneys. Besides being excessive, the kidneys were the only tissue with levels dependent upon chain length (e.g. at 1 hr, 5, 7 and 22 ID%/g for MORF15, 18 and 25, respectively) and sequence (e.g. at 3 hrs 9 ID%/g for MORF25 and 21 ID%/g for cMORF25). Identical biodistribution trends were observed in tumored mice with all tissues including tumor showing levels independent of chain length or base sequence except for kidneys. Furthermore, while all other tissues cleared in the interval from 1-3 hrs, kidney levels remained constant in both normal and tumored animals. Largely because of these differences in kidneys, images obtained by pretargeting with 99mTc-cMORF15 were superior compared to 99mTc-cMORF18 (images of control animals not receiving the antibody showed no tumor at all).


CONCLUSIONS
Judged by radiolabel accumulations in tissue, the pharmacokinetics of 99mTc labeled morpholinos were independent of chain length and base sequence. The only obvious exception was kidneys in which accumulations were significantly higher for the longer chain lengths and significantly different for cMORF vs MORF. These results show that chain length and base sequences may be varied to alter the pharmacokinetics of radiolabeled oligomers in nuclear medicine imaging studies.
Liu
G
G
Department of Radiology, University of Massachusetts Medical School, Worcester, MA 01655-0243, USA.
Zhang
S
S
He
J
J
Liu
N
N
Gupta
S
S
Rusckowski
M
M
Hnatowich
D J
DJ
D000818:Animals; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000737:chemistry / Q000493:pharmacokinetics*; D007553:Isotope Labeling / Q000379:methods; D051379:Mice; D008819:Mice, Nude; D008969:Molecular Sequence Data; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000378:metabolism*; D009841:Oligonucleotides / Q000737:chemistry / Q000493:pharmacokinetics*; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics*; D015609:Organotechnetium Compounds / Q000737:chemistry / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012016:Reference Values; D012680:Sensitivity and Specificity; D014018:Tissue Distribution
D014408:Biomarkers, Tumor; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C451036:technetium MAG3-cMORF